Manufactures pharmaceutical formulations spanning cardiac, diabetic, dermatology and ENT therapy areas, selling both in India and overseas markets. Exports are diversified across African, Latin American, South-East Asian, institutional-tender and Canadian markets, with a Cepha manufacturing block now past breakeven and Canadian sales run through 6 Health Canada-approved product lines. R&D spend is being stepped up to support growing dossier filings, while the company is exploring entry into oncology and hormones alongside inorganic acquisitions in tablet and injectable manufacturing. Materials (35.7% of revenue) and employee costs (18.7%) are the largest cost lines, and management has guided to an INR1,000 crore revenue target with a stated 5-6 month slippage buffer on the original FY28 timeline. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Cardiac, diabetic, dermatology and ENT formulations, Domestic sales, Africa exports, Latin America and South-East Asia exports, Institutional tender business, Canada and other regulated markets, Cepha manufacturing block. Mid-sized, formulation-driven Indian pharma with export-heavy mix and a diversified therapy portfolio.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 472 | 510 | 581 | 623 | 671 |
| EBITDA (ex other income) | 95 | 89 | 100 | 101 | 98 |
| margin % | 20.2 | 17.5 | 17.2 | 16.3 | 14.6 |
| Owners' profit | 69 | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | 34.63 | 36.40 | 46.58 | 41.11 | 43.88 |
| ROE % · ROCE % | 16.0 · 21.9 | 14.5 · 19.9 | 15.7 · 20.3 | 12.3 · 16.1 | 11.6 · 15.0 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Cash from operations | 76 | 39 | 63 | 93 | 106 |
| Capex | (46) | (14) | (39) | (19) | (25) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Profit before tax | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Net profit | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS (₹) | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Sept 2026 · Newspaper publication for 32nd AGM, book closure and e-voting info | compliance | minimal | — | — |
| 5 Sept 2026 · Physical AGM notice and Annual Report link sent to shareholders without registered emails | compliance | minimal | — | — |
| 5 Sept 2026 · Lincoln Pharma files 32nd AGM notice and annual report for FY26 | results | high | — | — |
| 5 Sept 2026 · Notice of 32nd AGM on September 30, 2026 via Video Conferencing | board shareholder meetings | low | — | — |
| 29 Aug 2026 · Lincoln Pharma final dividend Rs 1.80; record date Sept 11 | corporate actions | high | — | — |
| 29 Aug 2026 · Lincoln Pharma Sep 12-30 book closure for Rs 1.80 final dividend; AGM Sep 30 | board shareholder meetings | low | — | — |
| 26 Aug 2026 · Lincoln Pharma 32nd AGM notice published in newspapers | compliance | minimal | — | — |
| 14 Aug 2026 · Lincoln Pharma Q1 FY27 results published in newspapers | compliance | minimal | — | — |
| 13 Aug 2026 · Lincoln Pharma Q1 FY27 net profit up 30.9% YoY to Rs 36.23 cr | results | high | — | — |
| 13 Aug 2026 · Lincoln Pharma Q1 FY27 net profit up 31% YoY to Rs 36.23 cr | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.9 | 28.9 | 36 of 169 | 79% |
| P/B | 1.6 | 3.3 | 42 of 163 | 75% |
| ROCE | 14.8 | 10.8 | 65 of 183 | 65% |
| ROE | 11.6 | 10.4 | 75 of 171 | 57% |
| Debt / Equity | 0.0 | 0.1 | 47 of 171 | 73% |
| EBITDA margin | 29.2 | 17.5 | 39 of 165 | 77% |
| Revenue growth | 15.1 | 16.3 | 83 of 161 | 49% |
| Profit growth | 30.9 | 30.9 | 80 of 158 | 50% |
| Market cap | 1244 | 839 | 85 of 182 | 54% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
